Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

PWRM, AMLN

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Saturday October 31, 2009

DrStockPick.com Stock Report!

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type

...

Amylin Pharmaceuticals (AMLN) reported a loss of 19 cents per share in the third quarter, which was narrower than the Zacks Consensus Estimate of a loss of 30 cents. In the prior-year period, the company had incurred a loss of 47 cents. Total revenues for the quarter were $211.2 million, down 3.3% year over year.   Revenues consisted of $192.9 million in product sales and $18.3 million in collaborative payments from partner Eli Lilly (LLY). Product sales comprised $171.1 million in sales of Byetta and $21.8 million in sales of Symlin. Byetta sales declined both on a yearly and sequential basis. The company attributed the sequential decline in Byetta sales to an increase in wholesaler stocking in the previous quarter. We believe Byetta continues to be affected by safety issues surrounding the use of the drug.   Selling, general and administrative expenses decreased to $80.1 million from ...

Last week, Merck (MRK) received a favorable opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin). The committee recommended the drugs to be used as add-ons to insulin for the treatment of type 2 diabetes.

In the US, a supplemental New Drug Application (sNDA) for the use of Januvia and Janumet in combination with insulin has been accepted by the FDA and is currently under review.

While the favorable opinion from the committee is good news, we remain concerned about the risk of inflamed pancreas for patients treated with Januvia or Janumet. Although the company officials refuse to accept the link, the FDA has stated that 88 cases of acute pancreatitis, including two cases of hemorrhagic or necrotizing pancreatitis, had been reported since the drug's approval in October 2006 through February 2009. Among

...

Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin's "phybrid" technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification of a peptide therapeutic should help Amylin expand its diabetes product ...

On July 20, 2009, Amylin Pharmaceuticals Inc., (AMLN), Eli Lilly and Company (LLY) and Alkermes Inc. (ALKS) announced that their co-developed drug for type II diabetes, Exenatide once weekly was more effective in reducing average blood sugar over three months compared to Sanofi-Aventis' (SNY) Lantus (insulin glargine) on the basis of a 26-week open-label, clinical study in 467 patients with type II diabetes. Exenatide once weekly treatment also resulted in a mean weight loss of 5.8 pounds at 26 weeks, compared to a mean weight gain of 3.1 pounds for the Sanofi drug. This is again a desirable result as obesity is one of the primary causes of type II diabetes. Further, there were fewer cases of confirmed hypoglycemia (over-reduction in blood sugar) in patients treated with Exenatide once weekly compared to Lantus.  More than 23 million people in the U.S. are affected by diabetes, ...

NDA acceptance not enough for Alkermes On July 7, 2009, Alkermes, Inc. (ALKS), Eli Lilly (LLY) and Amylin Pharmaceuticals, Inc. (ALNY) announced the acceptance of the New Drug Application (NDA) for once-a-week diabetes drug Exenatide by the U.S. Food and Drug Administration (FDA). Exenatide once weekly is being co-developed by the three companies for type II diabetes. The application was filed by Alkermes in May 2009. Exenatide is an active ingredient of Byetta injection. It is presently available in the U.S. and in many countries across the globe as a treatment for type II diabetes patients who fail to achieve good glycemic control with commonly available oral therapies. Byetta is injected twice a day as against the once a week administration of the proposed drug. If approved, Exenatide once weekly would be the first and only once-a-week therapy for the treatment of ...

Eli Lilly and Company (LLY) turned in a solid year in 2007 and again in 2008. 2008 sales increased by 9% on strong sales of Cymbalta, Alimta, Byetta, Cialis and the Animal Health business. EPS grew even faster, at 13%, as operating margins widened on stronger gross margins and modest SG&A leverage. For 2009 Lilly expects EPS between $4.00 and $4.25 on revenue growth in the mid-single digits.While we've been mildly surprised by the annual performance in 2007 and 2008, for the reasons that we've discussed above, we don't believe the stock will outperform.Strong sales from key products such as Cymbalta, Cialis and Alimta will be the fundamental strength to EPS growth from 2008 through 2010. The addition of ImClone will add incremental revenue growth but will be highly dilutive to GAAP EPS for at least the next several years.Longer-term, we are ...

Eli Lilly and Company (LLY) turned in a solid year in 2007 and again in 2008. 2008 sales increased by 9% on strong sales of Cymbalta, Alimta, Byetta, Cialis and the Animal Health business. EPS grew even faster, at 13%, as operating margins widened on stronger gross margins and modest SG&A leverage. For 2009 Lilly expects EPS between $4.00 and $4.25 on revenue growth in the mid-single digits.While we've been mildly surprised by the annual performance in 2007 and 2008, for the reasons that we've discussed above, we don't believe the stock will outperform.Strong sales from key products such as Cymbalta, Cialis and Alimta will be the fundamental strength to EPS growth from 2008 through 2010. The addition of ImClone will add incremental revenue growth but will be highly dilutive to GAAP EPS for at least the next several years.Longer-term, we are ...

For Immediate Release

Chicago, IL - June 9, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amylin Pharmaceuticals (AMLN), Merck (MRK), Glaxo (GSK), Bristol (BMY) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Amylin Update Post ADA Meeting

This past weekend, Amylin Pharmaceuticals (AMLN) presented several abstracts and oral presentations at the American Diabetes Association (ADA) meeting in New Orleans. At the meeting, Amylin presented long-term follow-up data from the 74-week open label portion of the DURATION-1 program that demonstrated

...